Kodein Dak (Codeine Phosphate Sesquihydrate)

Codeine phosphate is converted in the body to morphine, which binds to mu‑opioid receptors in the central nervous system. This binding reduces the release of neurotransmitters involved in pain signaling and dampens the cough reflex, providing both analgesic and antitussive effects.

The appropriate dose of Kodein Dak is determined by the prescribing clinician based on the individual’s condition, age, weight, and response to therapy. Dosage regimens are not standardized in public information and should follow the prescriber’s instructions and local regulatory guidance.

Safety data for codeine phosphate in pregnancy and lactation are limited, and the drug is generally avoided unless the potential benefit outweighs the risk. It can cross the placenta and appear in breast milk, so healthcare providers usually recommend alternative treatments for pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Kodein Dak. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kodein Dak (codeine phosphate) is a weaker opioid compared with agents such as morphine or oxycodone, offering milder analgesia and a lower risk of severe respiratory depression when used appropriately. However, it still carries potential for dependence and may be less effective for severe pain, where stronger opioids are preferred.

Kodein Dak should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and excessive heat to maintain stability and potency throughout its shelf life.

Kodein Dak is formulated for oral use. The tablet (or oral dosage form) should be swallowed whole with water, unless the prescribing information advises otherwise. It is not intended for crushing, chewing, or sublingual administration.

The most serious risks include respiratory depression, especially when combined with other central nervous system depressants, and the potential for dependence, addiction, or misuse with prolonged therapy. Severe allergic reactions and rare liver toxicity are also possible and require immediate medical attention.

Kodein Dak should be avoided in individuals with known hypersensitivity to codeine or other opioids, those with severe respiratory insufficiency, children without specialist supervision, and patients taking monoamine oxidase inhibitors. It is also contraindicated in patients with significant hepatic impairment or a history of opioid addiction.